Gonorrhea (Neisseria Gonorrhea) | Pathophysiology, Symptoms & Complications, Diagnosis, Treatment

Main ideas / lessons conveyed

What gonorrhea is

• Gonorrhea is caused by the bacterium Neisseria gonorrhoeae (referred to in subtitles as “neria ganaria”).
• It is primarily a sexually transmitted infection (STI), but it can also cause other localized infections and serious complications.

How it spreads

• Sexual transmission via sexual contact.
• Vertical transmission: transmission during vaginal delivery, infecting the newborn, which can lead to eye disease and risk of systemic infection.
• Gonorrhea can co-occur with other STIs, especially chlamydia.

Risk factors

• Unprotected sexual activity
• Multiple sex partners
• Male homosexuality (as stated)
• History of previous STIs
• Illicit drug use (as stated)

Key microbiology / pathophysiology

• Gram-negative diplococci
  • Pink on Gram stain
  • “Diplococci” = paired cocci
• Obligate intracellular pathogen
  • Survives/replicates inside host cells
• Hosts and strains
  • Humans are the main natural host; multiple strains exist, including:
    • Serum-sensitive strains (more vulnerable to complement)
    • Serum-resistant strains (can evade complement, more able to cause severe/disseminated disease)

Invasion and adherence

• Adheres to mucous membranes using pili (hairlike strands) to attach and move between cells.
• Uses Opa (opacity-associated) proteins for additional attachment/invasion.
• Can enter host cells using interactions with host receptors (described as CR3 in the subtitles).

Affected sites (mucous membranes)

• Lower urogenital tract (most common)
• Pharynx (throat)
• Anus/rectum
• Conjunctiva (eyes; especially in neonates via vertical transmission)

Host response and symptom basis

• After infection, the immune response leads to purulence and cell sloughing, contributing to discharge and other symptoms.

Transmission rates and incubation

• Incubation period: about 1–14 days (often <10 days)
• Per-contact transmission risk:
  • Male → female: 50–70%
  • Female → male: 20%
• Spread can occur via pre-ejaculate/semen/vaginal fluid
  • Subtitles describe attachment to sperm via lipopolysaccharide (LPS).

---

Symptoms and clinical syndromes (by population)

1) Males

• Urethritis (inflammation of the urethra)
• Most symptomatic:
  • >90% of infected males have symptoms (as stated)

Lower urinary tract symptoms (LUTS)

• Dysuria (burning with urination)
• Urinary frequency/urgency

Urethral discharge

• Starts as clear fluid
• Then about 3 days later becomes purulent (pus-like, white discharge)

Complications

• Acute epididymo-orchitis
  • Often unilateral
  • Scrotal pain and fever
• Urethral strictures
  • Typically after untreated infection
  • Can cause urination problems or an intermittent urine stream

2) Females

• Symptoms occur in <50% of infected women (as stated)

Most common initial symptom

• Purulent vaginal discharge (may be thin/odoriferous)

Other genital symptoms

• Dysuria
• Dyspareunia (painful intercourse)
• Abnormal uterine bleeding
  • Intermenstrual bleeding
  • Postcoital bleeding (after sex)
  • Postmenopausal bleeding

Pelvic inflammatory disease (PID)

• Via retrograde spread (~20% as stated)
• Pain patterns:
  • Right lower quadrant pain
  • Pelvic pain
• May include fever
• Possible nausea/vomiting (less common)

Pregnancy-related complications

• Preterm birth
• Infertility (including due to lack of symptoms → untreated infection)
• Ectopic pregnancy (implantation outside uterus, e.g., in fallopian tubes)
• Low birth weight / birth-related complications mentioned (subtitles phrase as “birth hin gland abscesses” is unclear, but “birth … abscesses” is likely referring to pregnancy complications and/or neonatal outcomes)

3) Other sites / special conditions

• Rectal gonorrhea (noted with male-to-male transmission)

  • Proctitis (rectal inflammation)
  • Itching
  • Rectal pain
  • Tenesmus: feeling of needing to defecate without actually needing to

• Ophthalmia neonatorum (neonatal eye infection)

  • From vertical transmission during vaginal delivery
  • Causes bilateral conjunctivitis
  • Symptoms: red, sore, burning eyes, purulent discharge, crusting
  • Neonates are also at risk for systemic infection

• Disseminated gonococcal infection (DGI) (rare; ~1% as stated)

  • More likely with serum-resistant strains
  • Symptoms:
    • Fever
    • Rash
    • Migratory polyarthritis (painful swollen joints that move)
    • Tendinitis
    • Meningitis
    • Endocarditis

---

Diagnosis methodology (structured)

Clinical assessment

• History and physical exam
  • Look for risk factors
  • Look for typical symptoms (e.g., purulent urethral/vaginal discharge, PID signs)

Physical exam findings (when applicable)

• Cervical friability (easy bleeding on contact)
  • Helps explain intermenstrual, postmenopausal, and postcoital bleeding
• Cervical motion tenderness
  • Suggests pelvic inflammatory disease

Laboratory testing options

• Swab testing

  • Swab purulent discharge to detect organism

• First-catch urine

  • Emphasized as important for gonorrhea sampling
  • Contrasts with “midstream urine” approaches used for some other UTI evaluations

• Bacterial culture

  • Microscopy/culture can show gram-negative diplococci
  • Described as:
    • Gold standard, but
    • Takes 24–72 hours
    • Can fail due to issues with sample viability during collection/transport

• NAAT (nucleic acid amplification test)

  • More common due to higher sensitivity and specificity
  • Detects bacterial genetic material without needing growth of live bacteria

Public health note

• Gonorrhea is described as a notifiable disease (e.g., reporting to CDC in the US).

---

Treatment methodology (structured, by scenario)

Uncomplicated gonorrhea (general)

• Ceftriaxone (described as “SE/ triaxone” → ceftriaxone)
  • 500 mg IM once (one dose)

Alternatives (as listed in subtitles)

• Cefixime 800 mg PO once
• If cephalosporin allergy:
  • Gentamicin 240 mg IM once (as stated)

Add chlamydia coverage because co-infection is common:

• Azithromycin (Azi)
  • 1–2 g PO once (often 1 g, sometimes 2 g; higher dose → more side effects such as nausea/vomiting)
• Or doxycycline
  • 100 mg PO BID for 7 days

Gonorrhea with meningitis

• Ceftriaxone 1–2 g IV
• Hospitalization
• Dosing interval:
  • Every 12–24 hours for weeks depending on severity
• Also treat possible chlamydia:
  • Azithromycin 1 g PO once (as stated)

Disseminated or complicated presentations (as stated)

• Septic arthritis / conjunctivitis
  • Ceftriaxone 1 g IM
  • Plus azithromycin 1 g PO once

Pelvic inflammatory disease (PID)

• Ceftriaxone 2 g IM
• Plus doxycycline
  • 100 mg PO BID for 14 days
• Metronidazole
  • May be added depending on likely organisms (subtitles say it “may be added and may not”)

Epididymo-orchitis

• Ceftriaxone 250 mg IM
• Plus doxycycline
  • 100 mg PO BID for 10 days

Antimicrobial resistance note

• Gonorrhea has developed increasing resistance:
  • Resistance described against penicillin
  • Also resistance to older macrolides
• Therefore, avoid using azithromycin alone; treat both gonorrhea and chlamydia as described.

---

Speakers / sources featured (as stated or identifiable)

• No individual speakers were named in the subtitles.
• Source mentioned: CDC (Centers for Disease Control and Prevention) (the agency referenced for reporting notifiable diseases).